BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 24788697)

  • 1. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
    Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
    PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
    Xu K; Yang S; Zhao Y
    Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
    Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.
    Lorusso D; Cirillo F; Mancini M; Spatti GB; Grijuela B; Ditto A; Raspagliesi F
    Oncology; 2013; 85(2):122-7. PubMed ID: 23941904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
    Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R
    Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
    Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
    Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
    Gallagher DJ; Konner JA; Bell-McGuinn KM; Bhatia J; Sabbatini P; Aghajanian CA; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Ann Oncol; 2011 May; 22(5):1127-1132. PubMed ID: 21084428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Zaaijer LH; van Doorn HC; Mourits MJ; van Beurden M; de Hullu JA; Adank MA; van Lonkhuijzen LR; Vasen HF; Slangen BF; Gaarenstroom KN; Zweemer RP; Vencken PM; Seynaeve C; Kriege M
    Br J Cancer; 2016 Nov; 115(10):1174-1178. PubMed ID: 27755534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
    Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
    Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    Vencken PM; Reitsma W; Kriege M; Mourits MJ; de Bock GH; de Hullu JA; van Altena AM; Gaarenstroom KN; Vasen HF; Adank MA; Schmidt MK; van Beurden M; Zweemer RP; Rijcken F; Slangen BF; Burger CW; Seynaeve C
    Ann Oncol; 2013 Aug; 24(8):2036-42. PubMed ID: 23543211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
    Safra T; Lai WC; Borgato L; Nicoletto MO; Berman T; Reich E; Alvear M; Haviv I; Muggia FM
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii63-viii68. PubMed ID: 24131973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.